LOS ANGELES–(BUSINESS WIRE)–GoldbergLaw PC announces that it is investigating SCYNEXIS, Inc.(“SCYNEXIS” or the “Company”) (Nasdaq: SCYX) concerning possibleviolations of federal securities laws.
If you purchased or otherwise acquired SCYNEXIS shares and would likemore information regarding the investigation, we encourage you to clickhere, or contact MichaelGoldberg or Brian Schall,of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA90067, at 800-977-7401, to discuss your rights without cost to you. Youcan also reach us through the firm’s website at http://www.Goldberglawpc.com,or by email at email@example.com.
On March 2, 2017, SCYNEXIS revealed that the U.S. Food and DrugAdministration (“FDA”) has issued a hold on clinical trials for theintravenous formulation of the Company’s lead product candidate SCY-078“until the FDA completes a review of all available pre-clinical andclinical data.”
SCYNEXIS informed shareholders that “[t]he clinical hold decision wasissued by the FDA following a review of three mild-to-moderatethrombotic events in healthy volunteers receiving the IV formulation ofSCY-078 at the highest doses and highest concentrations in a Phase 1study.”
When this information was revealed to investors, the value of SCYNEXISfell, causing investors harm.
If you have any questions concerning your legal rights, pleaseimmediately contact Goldberg Law PC at 800-977-7401, or visit ourwebsite at http://www.Goldberglawpc.com,or email us at firstname.lastname@example.org.
Goldberg Law PC represents shareholders around the world and specializesin securities class actions and shareholder rights litigation.
This press release may be considered Attorney Advertising in somejurisdictions under the applicable law and ethical rules.